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Potential drugs
Overview of presentation
Part 1
• Introduction to Thermally Stimulated Current 
Spectroscopy (TSC)
• Examples (amorphous, polymorphs, co-crystals)
Part 2
• Thermal Analysis by Structural Characterisation
• Thermal Dissolution Analysis (TDA)
• Conclusions
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TSC is a general term applied to the measurement of current
generated by temperature-activated relaxation of molecular
dipoles in response to the application of a static electric field
• 1936, Frei and Grotzinger
• electrets, ionic crystals 
• waxes, resins
• ceramics, plastic
• small organic molecules
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Introduction to TSC
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Introduction to TSC
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TSC Theory
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Arrhenius equation
Eyring equation
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Potential drugs
Pharmaceutical Applications
• Amorphous materials
• Polymorphs
• Batch-to-batch control
• Co-crystals 
ESTAC 11 20/08/2014
Global glass 
relaxation process
Different relaxation 
modes contributing 
to overall process
TW outputs
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Defining Ea - (TW)
Tp(°C) Tmax(°C)
Ea 
(kJ/mol)
ΔH‡
(kJ/mol)
12 35 90 87
14 37 93 90
16 38 104 101
18 39 112 109
20 41 126 123
22 42 135 132
24 43 145 142
26 43 157 154
28 44 171 169
30 45 190 188
32 45 208 205
34 46 225 222
36 46 246 244
38 47 259 257
40 48 273 270
42 50 298 295
𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭 𝑰𝑰𝑰𝑰𝑰𝑰𝑰𝑰𝑰𝑰 (𝒎𝒎) = 𝟏𝟏
𝟐𝟐.𝟑𝟑𝟑𝟑𝟑𝟑 𝟏𝟏𝑬𝑬𝑭𝑭 (𝑻𝑻𝑭𝑭)𝑹𝑹𝑻𝑻𝑭𝑭
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Fragility - Indometacin
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Tm (K) Ea (kJmol-1) τ (s) m
TSDC (Tp = 303 K) 314.4 (0.1) 376.0 (3.3) 59.3 (9.0) 62.4 (3.3)
TSDC (Tp = 313 K) 314.3 (0.1) 388.3 (4.0) 54.8 (8.0) 64.5 (4.0)
TSDC (Tp = 323 K) 314.5 (0.1) 385.8 (3.2) 51.4 (7.4) 64.1 (3.2)
Integration
window (K)
Tmax (K) Ea (kJmol-1) m
TSDC (Tp = 303 K) 20 314.4 (0.1) 138.8 (1.0) 23.1 (1.0)
10 314.4 (0.1) 178.3 (1.8) 29.6 (1.9)
5 314.4 (0.1) 232.3 (1.0) 38.6 (1.0)
TSDC (Tp = 313 K) 20 314.3 (0.1) 139.8 (1.5) 23.2 (1.5)
10 314.3 (0.1) 180.2 (1.2) 30.0 (1.2)
5 314.3 (0.1) 244.4 (2.3) 40.6 (2.3)
TSDC (Tp = 323 K) 20 314.5 (0.1) 141.2 (1.5) 23.4 (1.5)
10 314.5 (0.1) 183.6 (2.5) 30.5 (2.0)
5 314.5 (0.1) 251.5 (1.4) 41.8 (1.4)
Integration window 2 K
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Potential drugs
Pharmaceutical Applications
• Amorphous materials
• Polymorphs
• Batch-to-batch control
• Co-crystals 
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Caffeine
Exists in two polymorphic forms:
Form I, unstable at room T, Trigonal
Form II, stable at room T, Monoclinic
Transition point: 141 ± 2°C
Melting Point: 236 - 243°C (British Pharmacopoeia)
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Caffeine - TSDC Results
Form I                            Form II
α-process 139ºC Form II only - polymorphic transition
γ-process -8ºC Forms I and II - orientation of side group
β1-process 91ºC Form II
β2-process 107ºC Form I - orientation/mobility of sub-unit
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Caffeine - SDC Results
Form I - negative peak at -8oC and 112oC
Form II - negative peak at 52oC
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Kinetic Parameters - TSC Method
TSDC                                      SDC
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Pharmaceutical Applications
• Amorphous materials
• Polymorphs
• Batch-to-batch control
• Co-crystals 
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Batch to Batch variations
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Pharmaceutical Applications
• Amorphous materials
• Polymorphs
• Batch-to-batch control
• Co-crystals 
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Potential drugs
• 1:1 molar ratio co-crystal (CC) of salicylic acid (SA) and benzamide (BA)
• 1:1 molar ratio physical mixture (PM)
SA/BA co-crystal system
Primary transitions:
BA = 128oC
SA = 159oC
CC = 119oC
PM = 110oC
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Potential drugs
SA/BA co-crystal system
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Potential drugs
SA/BA co-crystal system
Tc:
CC-A = 125oC
CC-B = 119oC
PM= 110oC
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Potential drugs
Part 2
• Thermal Analysis by Structural 
Characterisation (TASC)
• Thermal Dissolution Analysis (TDA)
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TASC consists of imposing a pattern on the surface of a sample
or exploiting pre-existing structure, then characterizing how
that pattern changes as the sample is heated; in this case
Optical Microscopy was used but it can be applied to other
forms of microscopy such as electron microscopy and Atomic
Force Microscopy.
heat
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The TASC algorithm scans an area
and tries to identify whether a
designated structure exists and
where it is located. Top right there is
a schematic of an indentation,
underneath this is the result of a
TASC analysis.
Right is a 3D representation of the
output of the TASC analysis. The apex
of the cone provides the location of
the feature
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It is important that the algorithm is
robust because it must deal with
non-ideal samples. Above right
there is a schematic of 4
indentations in a ‘noisy’ background.
Below this is the result of a TASC
analysis.
Right is a 3D representation of the
output of the TASC analysis with the
noisy background.
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Above shows a series of schematic indentations
of decreasing size. The degree of recognition by
the TASC algorithm decreases as the size of the
indentation decreases.
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This is graph showing a co-plot of DSC and TASC data.
The flow event happens after the glass transition as
measured by DSC as expected.
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An ideal form of microscopy is
Atomic Force Microscopy. Below is a
comparison of an AFM result
(circles), on an indentation 500nm in
diameter with one obtained using
optical microscopy on an indentation
200m in diameter (squares).
130oC
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Potential drugs
Part 2
• Thermal Analysis by Structural 
Characterisation (TASC)
• Thermal Dissolution Analysis (TDA)
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Right is an image of a collection
of sugar crystals in water in a DSC
crucible. The TASC algorithm can
follow their disappearance.
In the graph shown right; it can
be seen that small crystals D, F
and G disappear much faster
than the large crystal I.
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Right shows a reduced
time plot of all of the
crystals.
Right, averaged data are
plotted against (1-a)3, an
approximately linear
graph is obtained as
would be expected for a
shrinking 3D object.
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Thermal Dissolution Analysis
TASC is used to track the dissolution of the salicylic acid
crystals in the field of view of the microscope. The
temperature program was 5oC/min.
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Thermal Dissolution Analysis
TASC is used to track the dissolution of the objects in the
field of view of the microscope. The temperature program
was 5oC/min.
Fr
ac
tio
n 
di
ss
ol
ve
d
Temp. /oC
ACAIII 30/09/2014
00.1
0.2
0.3
0.4
0.5
0.6
0.7
0 500 1000 1500
Thermal Dissolution Analysis
A line was fitted to the linear part of the dissolution curves
and the gradients were plotted against the size of the
crystals.
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The dissolution behavior clears falls into two categories
shown as red and green.
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The objects in the field can be allocated to the two
categories.
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i)
ii)
iii)
iv)
CIDA
Filtered i) from solvent; iii) from residue
By appropriate chemical analysis the ‘red’ and
‘green’ materials can be identified.
Glucose Salicylic Acid
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It is typically the case that different material have different
dissolution kinetics.
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Thermal Dissolution Analysis
TGA-GC-MS Mass Loss Chromatography
Chromatography‘Volume’ LossTDA-HPLC
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Conclusions
TSC
• Detection and characterisation of amorphous materials
• Characterisation (Kinetics) of polymorphic transitions and co-crystal 
systems
• Detection of beta and gama relaxation processes
• Links between secondary (beta and gama) and primary relaxation
• Batch to batch variations
TASC/TDA
• Molecular mobility at a micro and potentially nano scale
• Surface structural analysis
• Dissolution kinetics of different materials in different solvents
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Thank you for 
listening 
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